The U.S. Food and Drug Administration has approved the first-in-human clinical trial of a new technology, which will be a joint effort between Cornell University, in Ithaca, New York, and Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City. The trial will study the effectiveness of Cornell Dots, nanoparticles that light up cancer cells in PET-optical imaging.
Already considered a breakthrough in cancer diagnostics technology, Cornell Dots may help identify aggressive cancers sooner. Mesothelioma, a rare cancer of the protective lining of the lungs, heart, chest and abdomen caused by prolonged asbestos exposure, is a particularly difficult cancer to detect. This silent killer takes decades to develop and does not become symptomatic until it reaches later stages. Malignant mesothelioma is often misdiagnosed and, even when diagnosed properly, it is rarely detected early enough to preserve the patient’s life. The development improved diagnostic tools absolutely is absolutely essential to winning the battle against mesothelioma disease.
Cornell Dots are the first nanoparticles to meet the criteria necessary to receive FDA approval for a study. The dots have, therefore, proven themselves “tumor selective, nontoxic, and exhibit favorable targeting and clearance profiles.”
The silica nanoparticles are coated in polyethylene glycol (PEG) so the body does not target them as an invading or harmful agent. They are then allowed to stick to tumor cells through organic molecules that attach to the PEG shell. Infrared light caused the dots to light up and serve as a honing beacon for cancerous cells.
According to the researchers, this new technology “enables visualization during surgical treatment, showing invasive or metastatic spread to lymph nodes and distant organs, and can show the extent of treatment response.”
This entry was posted on Friday, July 15th, 2011 at 10:17 am and is filed under New York, News.